title: Toxicity of 2,2',4,4',5,5'-hexachlorobiphenyl in rats: effects following 90-day oral exposure.
abstract: The subchronic toxicity of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) was investigated in rats after 13 weeks of dietary exposure. Groups of 10 male and 10 female rats were administered PCB 153 in their diet at levels of 0.05, 0.50, 5.0 or 50 ppm for 13 weeks. The control groups received the diet containing 4% corn oil. Growth rate and dietary consumption were not affected by treatment. Clinical signs of toxicity were not observed. Enlarged, fatty liver was observed in treated animals at necropsy, but most were confined to the two highest dose groups. Increased hepatic microsomal ethoxyresorufin-O-deethylase, aminopyrine-N-demethylase and aniline hydroxylase activities occurred in high-dose groups of both sexes, with increased ethoxyresorufin-O-deethylase activity being observed starting at 0.05 ppm in females and at 0.5 ppm in males. Treatment-related reduction in hepatic and pulmonary vitamin A was seen in the highest dose group of both sexes. Changes in brain biogenic amines and intermediate products were observed mainly in females; these included decreased dopamine and 5-hydroxytryptamine concentrations in the frontal cortex region, and dihydroxyphenylacetic acid in the caudate nucleus region at 5.0 and 50 ppm. Female rats appeared to be more sensitive to the neurotoxic effects of PCB 153 than males. Dose-dependent histological changes were observed in the thyroid and liver of rats of both sexes and significant changes occurred at 5.0 and 50 ppm. Based on these data, the no-observable-adverse-effect level (NOAEL) of PCB 153 was judged to be 0.5 ppm in the diet or 34 micrograms kg-1 body wt. day-1.
authors.affiliation: Environmental Health Directorate and Food Directorate, Health Protection Branch, Tunney's Pasture, Ottawa, Ontario, Canada.
authors.forename: I
authors.initials: I
authors.lastname: Chu
authors.forename: D C
authors.initials: DC
authors.lastname: Villeneuve
authors.forename: A
authors.initials: A
authors.lastname: Yagminas
authors.forename: P
authors.initials: P
authors.lastname: Lecavalier
authors.forename: R
authors.initials: R
authors.lastname: Poon
authors.forename: M
authors.initials: M
authors.lastname: Feeley
authors.forename: S W
authors.initials: SW
authors.lastname: Kennedy
authors.forename: R F
authors.initials: RF
authors.lastname: Seegal
authors.forename: H
authors.initials: H
authors.lastname: Håkansson
authors.forename: U G
authors.initials: UG
authors.lastname: Ahlborg
authors.forename: V E
authors.initials: VE
authors.lastname: Valli
authors.forename: A
authors.initials: A
authors.lastname: Bergman
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D019363:Cytochrome P-450 CYP1A1 / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000097:blood / Q000652:urine; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D011078:Polychlorinated Biphenyls / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013959:Thyroid Diseases / Q000139:chemically induced*; D013961:Thyroid Gland / Q000187:drug effects / Q000473:pathology; D014801:Vitamin A / Q000032:analysis / Q000378:metabolism
chemical_list: D014801:Vitamin A; D011078:Polychlorinated Biphenyls; D019363:Cytochrome P-450 CYP1A1; C014024:2,4,5,2',4',5'-hexachlorobiphenyl